



Christopher Bowen  
Managing Director and Chief Regulatory Counsel  
Legal Department

July 25, 2013

**VIA E-MAIL**

Ms. Melissa Jurgens  
Office of the Secretariat  
Commodity Futures Trading Commission  
Three Lafayette Centre  
1155 21st Street, N.W.  
Washington, D.C. 20581

CONFIDENTIAL TREATMENT  
REQUESTED

**Re: SUPPLEMENTAL SUBMISSION. Rule Certification. New York Mercantile Exchange, Inc. Submission #13-290S: Additional Supplemental Market Information**

Dear Ms. Jurgens:

Previously, pursuant to submission #13-290, dated July 25, 2013, the New York Mercantile Exchange, Inc. ("NYMEX" or the "Exchange") notified the Commodity Futures Trading Commission ("CFTC" or "Commission") that it was self-certifying the listing of a new Freight Route TC14 (Baltic) Futures contract (code FRC, chapter 1103) for trading on CME Globex and the NYMEX trading floor and for submission for clearing through CME ClearPort beginning at 6:00 p.m. on Sunday, July 28, 2013, for trade date Monday, July 29, 2013.

In this letter, the Exchange is providing the Commission with certain monthly price information applicable to the related cash market for the proposed contract's underlying market for the period beginning March 2012 through to April 2013.

The additional supplemental market information is provided in Appendix A, for which a request for confidential treatment is being simultaneously submitted to the CFTC pursuant to Rule 40.8 and Regulation 145.9(d). A copy of that request for confidential treatment is included with this supplemental filing.

Pursuant to Section 5c(c) of the Commodity Exchange Act ("Act") and CFTC Rule 40.2, the Exchange hereby certifies that the attached supplemental market information complies with the Act, including regulations under the Act.

The Exchange certifies that a description of the submission has been concurrently posted on the Exchange's website at <http://www.cmegroup.com/market-regulation/rule-filings.html>.

Should you have any questions concerning the above, please contact the undersigned at (212) 299-2200 or [Christopher.bowen@cmegroup.com](mailto:Christopher.bowen@cmegroup.com).

Sincerely,

/s/Christopher K. Bowen  
Managing Director and Chief Regulatory Counsel

Attachment: Appendix A: Additional Supplemental Information



Christopher Bowen  
Managing Director and Chief Regulatory Counsel  
Legal Department

July 25, 2013

**VIA E-MAIL**

Stacy Easter  
Paralegal Specialist  
FOIA Compliance Office  
Commodity Futures Trading Commission  
Three Lafayette Centre  
1155 21st Street, N.W.  
Washington, D.C. 20581

CONFIDENTIAL TREATMENT  
REQUESTED

**Re: FOIA Confidential Treatment Request**

Dear Ms. Easter:

By e-mail dated today, July 25, 2013, the New York Mercantile Exchange, Inc. ("NYMEX" or the "Exchange") submitted a product certification filing to the CFTC (submission 13-290S). This supplemental filing includes an appendix ("Appendix A"), which is attached.

The Exchange is also providing the Commission with a detailed written justification on behalf of NYMEX and The Baltic Exchange Limited ("Baltic Exchange") which sets forth grounds for this request for confidential treatment in Exhibit 1 herewith ("Exhibit 1").

Pursuant to Sections 8 and 8(a) of the Commodity Exchange Act ("CEA"), as amended, and Commission Regulation 145.9(d), NYMEX requests confidential treatment of Appendix A on the grounds that disclosure of Appendix A would reveal confidential commercial information of the submitter (NYMEX) and of Baltic Exchange.

Pursuant to Commission Regulation 145.9(d)(5), NYMEX requests that confidential treatment be maintained for Appendix A until further notice from the Exchange. We also request that the Commission notify the undersigned immediately after receiving any FOIA request for said Appendix A or any other court order, subpoena or summons for same. Finally, we request that we be notified in the event the Commission intends to disclose such Appendix A to Congress or to any other governmental agency or unit pursuant to Section 8 of the CEA. NYMEX does not waive its notification rights under Section 8(f) of the CEA with respect to any subpoena or summons for such Appendix A.

Please contact the undersigned at (312) 930-8167 should you have any questions concerning this letter.

Sincerely,

/s/Christopher K. Bowen  
Managing Director and Chief Regulatory Counsel

Enclosure